International Assets Investment Management LLC Has $113,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)

International Assets Investment Management LLC lifted its holdings in Personalis, Inc. (NASDAQ:PSNL) by 438.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,982 shares of the company’s stock after acquiring an additional 17,082 shares during the period. International Assets Investment Management LLC’s holdings in Personalis were worth $113,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of PSNL. ARK Investment Management LLC grew its position in shares of Personalis by 4.9% during the 2nd quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock worth $7,443,000 after purchasing an additional 296,413 shares in the last quarter. Acadian Asset Management LLC grew its position in Personalis by 6.7% during the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after buying an additional 66,128 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Personalis by 144.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after acquiring an additional 485,822 shares during the period. GSA Capital Partners LLP raised its holdings in Personalis by 6.2% in the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock valued at $626,000 after acquiring an additional 24,498 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Personalis by 58.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company’s stock valued at $142,000 after acquiring an additional 34,900 shares during the period. 61.91% of the stock is owned by institutional investors.

Analyst Ratings Changes

PSNL has been the subject of several recent analyst reports. BTIG Research upped their price objective on shares of Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Needham & Company LLC reiterated a “buy” rating and set a $7.25 price target on shares of Personalis in a research report on Thursday. Finally, HC Wainwright boosted their price objective on shares of Personalis from $7.50 to $9.00 and gave the company a “buy” rating in a research report on Monday, August 19th.

Personalis Trading Down 22.6 %

PSNL opened at $4.32 on Friday. The company has a market cap of $229.31 million, a P/E ratio of -2.63 and a beta of 1.94. The company’s 50 day moving average is $5.15 and its 200-day moving average is $3.32. Personalis, Inc. has a 1-year low of $0.89 and a 1-year high of $7.20.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. The company had revenue of $22.58 million during the quarter, compared to the consensus estimate of $19.81 million. During the same period in the prior year, the business earned ($0.50) earnings per share. On average, equities analysts forecast that Personalis, Inc. will post -1.15 EPS for the current year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.